Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct‐Acting Antiviral Treatment Failure in Patients With Hepatitis C?

Direct‐acting antiviral (DAA) therapies have revolutionized the treatment of chronic hepatitis C virus infection, achieving sustained virological response (SVR) rates of >90% even in patients with advanced liver cirrhosis. Having observed an unusual case of repeated DAA therapy failures in a pati...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Hepatol Commun
मुख्य लेखकों: Piecha, Felix, Gänßler, Jan‐Michael, Jordan, Sabine, Ergen, Can, Ittrich, Harald, Kluwe, Johannes, Pischke, Sven, Lohse, Ansgar W., Schulze zur Wiesch, Julian
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2019
विषय:
Brief Report
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492468/
https://ncbi.nlm.nih.gov/pubmed/31061950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1337
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन